Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Rheumatology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Juvenile idiopathic arthritis in transition to adult care

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Urgently assess a hot joint with fever, painful red or photophobic eye, acute neurological or cardiopulmonary symptoms, or systemic-JIA fever with falling blood counts and organ dysfunction. Transition arrangements must never become a barrier to same-day paediatric or adult emergency care.

Overview

Deliver planned, developmentally appropriate transition for young people with juvenile idiopathic arthritis, preserving disease control, uveitis surveillance, medicine safety, self-management and continuity across paediatric and adult services.

JIA includes oligoarticular, polyarticular, systemic, psoriatic, enthesitis-related and other phenotypes. Some remit; many remain active or leave structural and psychosocial consequences. Adult teams need the original category, antibody and HLA status, uveitis history, growth and surgery details, and complete treatment chronology. Simply relabelling the disease as adult RA can lose important screening and biological context.

NICE transition guidance recommends early planning, a named worker, developmentally appropriate information and coordinated health and social support. Readiness includes understanding disease, medicines, appointments, monitoring, emergency contacts, consent, confidentiality and self-advocacy. Assess cognitive, communication and social needs and maintain reasonable adjustments. Family involvement changes gradually with the young person's wishes and capacity.

Clinical review separates activity, damage and development. Examine joints, entheses, spine, growth-related alignment and function; assess eyes, skin and systemic features. Review uveitis screening rather than asking only about red eyes because chronic JIA uveitis can be asymptomatic. Check laboratory monitoring, immunisation, infection, bone health, exercise, pain amplification and mental wellbeing.

Aetiology

01

Heterogeneous childhood immune disease

JIA comprises several immune-mediated arthritis categories beginning before age sixteen, with genetic and environmental influences differing across phenotypes.

02

Autoinflammatory systemic disease

Systemic JIA is driven strongly by innate cytokine pathways and differs biologically from many autoantibody-associated or spondyloarthritis categories.

03

Adaptive autoimmune susceptibility

Oligoarticular and polyarticular categories reflect HLA-linked adaptive immune dysregulation; ANA marks phenotype and uveitis risk rather than identifying a single cause.

Pathophysiology

  1. 1
    Persistent synovial inflammation

    Immune activation maintains synovitis, pain and restricted growth or joint damage when control is delayed or treatment is interrupted.

  2. 2
    Silent ocular inflammation

    Chronic anterior uveitis may progress without pain or redness, making scheduled slit-lamp screening essential even when joints are quiet.

  3. 3
    Disease and treatment across maturation

    Changing body size, reproductive potential and organ reserve alter medicine dosing, toxicity, self-management and transfer responsibilities during adolescence.

Clinical features and red flags

Active inflammatory disease

New swollen joints, morning stiffness, enthesitis, dactylitis, systemic fever or declining function indicates activity requiring adult rheumatology treatment review.

Silent uveitis risk

Previous or high-risk JIA-associated uveitis can recur without symptoms, so documented slit-lamp surveillance must continue across transfer.

Transition-readiness gap

Uncertainty about medicine, monitoring, appointments, confidentiality or emergency access predicts unsafe transfer and requires further supported education.

Macrophage activation syndromeRed flag

Systemic-JIA fever with falling platelets, fibrinogen, liver dysfunction, coagulopathy or neurological change requires urgent multidisciplinary care.

Infection during immunosuppressionRed flag

Fever, one hot joint, respiratory compromise or systemic illness may be muted by treatment and needs acute infection assessment.

Investigations

  1. 01
    Structured transition-readiness assessmentFirst step
    Why
    Identify knowledge, self-management, communication and practical gaps before transfer.
    Interpretation and limitations
    Readiness is individual and dynamic; use the result to teach and support rather than to deny access or abruptly remove family help.
  2. 02
    Joint, enthesis, spine and functional assessment
    Why
    Document active disease, accumulated damage and rehabilitation needs for the adult baseline.
    Interpretation and limitations
    Pain can reflect synovitis, structural damage or amplification; record objective inflammation and limitations separately.
  3. 03
    Ophthalmic slit-lamp surveillance record
    Why
    Prevent loss of screening and treatment continuity for JIA-associated uveitis.
    Interpretation and limitations
    Absence of pain or redness does not exclude chronic anterior uveitis; the specialist interval follows risk and prior disease.
  4. 04
    FBC, renal, liver and inflammatory tests
    Why
    Provide current disease and medicine-safety information at transfer.
    Interpretation and limitations
    Verify who reviews abnormalities and whether trends reflect toxicity, infection, systemic activity or another diagnosis.
  5. 05

Differential diagnosis

01

Adult inflammatory classification

Persistent childhood disease may resemble adult RA, spondyloarthritis or Still disease, but the original phenotype and treatment history remain clinically important.

02

Infection or crystal disease

A newly hot joint or systemic illness during immunosuppression requires fresh infection assessment rather than attribution to established JIA.

03

Mechanical damage and pain amplification

Growth-related biomechanics, old joint damage, hypermobility, osteoarthritis and fibromyalgia can cause significant symptoms without current active synovitis.

04

Medicine toxicity or non-adherence

Cytopenia, liver injury, infection and missed dosing can mimic disease change and require confidential, nonjudgmental assessment.

Management

01PrepareBuild capability before transferFirst stepA young person with JIA is approaching adolescence or adult-service transfer.+
  1. 1Introduce transition early, identify a coordinator and assess disease knowledge, self-management, communication, education, mental health and family support.
  2. 2Provide repeated age-appropriate teaching on medicines, monitoring, uveitis, infection, reproductive health, prescriptions and emergency contacts with private consultation time.
  3. 3Agree a flexible transfer plan with paediatric and adult teams and the young person, including reasonable adjustments and explicit readiness gaps.
02TransferClose every ownership gapThe young person is moving prescribing and clinical responsibility to adult services.+
  1. 1Send a complete disease, uveitis, treatment, toxicity, vaccination, surgery, psychosocial and safeguarding summary before the first adult appointment.

Complications

01

Joint damage and growth effects

Persistent childhood inflammation can cause deformity, limb-length difference, growth disturbance, osteoporosis and lasting limitation into adult life.

02

Uveitis and visual loss

Undetected chronic anterior uveitis can produce cataract, glaucoma, synechiae and irreversible sight loss despite few ocular symptoms.

03

Macrophage activation syndrome

Systemic JIA can develop life-threatening cytokine activation with fever, cytopenia, coagulopathy, liver injury and neurological dysfunction.

04

Loss to follow-up

Poorly coordinated transfer can interrupt medicines, monitoring, contraception, uveitis screening and emergency access, causing preventable flare and harm.

Monitoring and follow-up

  • Confirm disease activity, function, pain and accumulated damage using measures meaningful to the adult phenotype.
  • Maintain the ophthalmology screening and treatment interval with named responsibility.
  • Check every DMARD or biologic blood-monitoring result and prescription handoff during transfer.
  • Review vaccination, infection, bone health, growth legacy, cardiovascular health and reproductive plans.
  • Track attendance, education, employment, mental health and confidence in self-management and respond supportively to gaps.

Special situations

Transition is not discharge

It is a supported developmental process whose success is measured by continuity, capability and outcomes after the administrative transfer.

Quiet joints do not quiet eyes

Chronic anterior uveitis may be asymptomatic and follow a different course, so slit-lamp surveillance must remain visible.

Adult labels can lose history

The childhood phenotype, growth effects and prior uveitis or MAS remain relevant even when adult classification resembles RA or SpA.

Confidentiality supports adherence

Private time allows honest discussion of missed doses, alcohol, sexual health, pregnancy and mental health while families remain valued partners.

Administrative ownership is clinical safety

A clear prescriber, blood-result reviewer and first appointment prevents interruption of potent medicines and monitoring.

Common pitfalls

  1. 01

    Beginning transition only at the final paediatric appointment.

  2. 02

    Assuming absence of eye symptoms makes uveitis screening unnecessary.

  3. 03

    Transferring without a confirmed adult appointment or medicine supply.

  4. 04

    Discussing teratogenic treatment only with young women rather than all relevant patients.

  5. 05

    Interpreting missed appointments as indifference without checking communication, cognition, transport, education and mental health.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
RheumatologyOriginal SBA

Essential transfer safeguard

A 17-year-old with JIA uses methotrexate and adalimumab and is due to leave paediatric care. Which action is most important before paediatric discharge?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Rheumatology topics →
Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG43 transition to adult servicesPlanning, coordination, developmentally appropriate care and transfer.
  • BSR 2025 conventional DMARD guidelineLife-course prescribing, transition, methotrexate monitoring and vaccination.
  • NHS England specialised rheumatology servicesSpecialised paediatric and adolescent rheumatology service context.
  • MHRA once-weekly methotrexate safetyPrevention of dosing errors during prescribing transitions.
  • RCOphth JIA uveitis screening guidelineAsymptomatic uveitis risk and continuing slit-lamp surveillance.
  • Adalimumab UK product informationContraindications, infection, vaccination and pregnancy-exposure safety.
  • BSR pregnancy prescribing guidelineMethotrexate and anti-TNF reproductive and infant-vaccine planning.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

Medication safety is vulnerable during transfer. Confirm prescriber, shared-care agreement, dose, weekly methotrexate day, biologic supply, blood-test owner and actions for infection or surgery. Discuss pregnancy, contraception and teratogenic drugs confidentially with all relevant young people. Plan flare access, university or travel supplies and communication with primary care before the paediatric team closes follow-up.

Key points

  • Transition is a planned process that begins early in adolescence; transfer is the single administrative event within it.
  • Identify a named coordinator and adult service, involve the young person directly and adapt timing to developmental readiness rather than eighteenth birthday alone.
  • Transfer a complete disease summary: JIA category, joint and extra-articular history, damage, uveitis, surgeries, medicines, failures, adverse reactions, monitoring, vaccines and current goals.
  • Continue ophthalmic screening at the interval set by the paediatric ophthalmology pathway; quiet joints do not prove quiet uveitis.
  • Teach the young person the medicine name, dose and schedule, laboratory plan, sick-day advice, contraception and pregnancy implications and how to request prescriptions.
  • Provide private consultation time and assess adherence, mental health, education, alcohol, smoking, sexual health, safeguarding and family support without abruptly excluding carers.
  • Methotrexate remains once weekly with folic acid separately; document pregnancy prevention and avoid accidental daily dosing during prescribing-system changes.
  • Confirm the first adult appointment and prescription responsibility before paediatric discharge; no young person should leave with an unowned monitoring result.
Medication reconciliation and reproductive review
Why
Prevent omitted, duplicated, wrongly dosed or teratogenic treatment during system change.
Interpretation and limitations
Confirm actual use, supply, adherence, weekly dose day, monitoring, contraception and pregnancy plans confidentially.
2
Confirm the adult appointment, medicine supply, shared-care prescriber, laboratory owner and urgent-access route before paediatric discharge.
  • 3Conduct joint review where possible and document the young person's goals, communication preference, consent and continuing family role.
    • 03Early adult follow-upCheck continuity, not only disease activityThe first adult-care months follow transfer or a missed appointment or prescription occurs.+
    1. 1Reconcile medicines, laboratory tests, uveitis screening and flare access and contact the young person using agreed methods after non-attendance.
    2. 2Assess inflammation, damage, pain, education, employment, mental health, sexual health and adherence without blame.
    3. 3Repair prescription or monitoring gaps immediately and review transition goals until the adult pathway is stable and understood.
    Key medicines and prescribing safety2 treatments · regimens, roles and cautions+
    Maintains control of persistent peripheral JIA phenotypes across transition when effective and tolerated.

    Methotrexate with folic acid

    Continue the verified specialist dose once weekly, commonly 7.5–25 mg in adult practice. Record one fixed dosing day and prescribe folic acid at least 5 mg once weekly on a different day.

    Never prescribe or take it daily. Confirm risk-based FBC, renal and liver monitoring and interacting medicines; withhold it during a serious infection until recovery and clinical review. For maternal exposure, low-dose methotrexate must be stopped at least 1 month before planned conception and is not compatible with pregnancy or breastmilk exposure; accidental pregnancy needs immediate cessation, folic acid 5 mg/day and specialist fetal-risk review. BSR regards paternal exposure at no more than 25 mg/week as compatible; ensure confidential contraception and specialist pre-conception planning before transfer.

    Biologic treatment for eligible persistent arthritis, enthesitis-related disease or uveitis under coordinated rheumatology and ophthalmology care.

    Adalimumab

    Continue the verified age-, weight- and indication-appropriate specialist regimen; adult maintenance is commonly 40 mg subcutaneously every other week.

    Screen for tuberculosis and hepatitis and stop for a serious active infection with acute specialist review. Avoid live vaccines during treatment; review demyelinating disease, and do not use in NYHA III or IV heart failure. When exposure continues beyond 28 weeks of pregnancy, document the BSR plan to defer infant live vaccines until 6 months.

    Content changes
    Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom